相关实验视频
Updated: Jun 22, 2025

07:22
Basophil Activation Test for Allergy Diagnosis
Published on: May 31, 2021
8.1K
在血管中接触系统激活和布拉迪基宁生成:实验室评估和生物标志物利用
Sandra C Christiansen1, Bruce L Zuraw2
1Department of Medicine, University of California San Diego, 9500 Gilman Drive, Mail Code 0732, La Jolla, CA 92093, USA.
Immunology and allergy clinics of North America
|June 27, 2024
概括
遗传性血管 (HAE) 病原体包括接触系统的激活. 新的研究探讨了正常C1抑制剂水平的HAE (HAE-nl-C1INH),确定了遗传联系和布拉迪基尼尼.
科学领域:
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
- 病理生理学 病理生理学
背景情况:
- 接触系统的激活是C1抑制剂缺乏 (HAE-C1INH) 的遗传性血管的关键.
- 在HAE-C1INH中,疾病活性与C1抑制剂 (C1INH) - 蛋白酶复合体,功能C1INH水平,血卡利克林激活和高分子量基因因素分裂相关.
- 具有正常C1抑制剂水平的遗传性血管 (HAE-nl-C1INH) 是一个公认的实体.
研究的目的:
- 为了研究HAE-nl-C1INH.H的病原性.
- 为了识别与HAE-nl-C1INH表型相关的遗传突变.
- 探索布拉迪基宁在HAE-nl-C1INH攻击中的作用.
主要方法:
- 对患有HAE-nl-C1INH的个体进行遗传分析.
- 生物化学测试用于评估接触系统组件.
- 临床评估疾病活动和胀发作.
主要成果:
- 在患有HAE-nl-C1INH的个体中,已经确定了6种基因突变.
- 很大一部分HAE-nl-C1INH病例仍然没有遗传定义.
- 有证据表明,布拉迪基宁生成有助于一些HAE-nl-C1INH患者的胀发作.
结论:
- 对HAE病原体的理解正在扩展到C1抑制剂缺乏症之外.
- 遗传因素和布拉迪基宁通路与HAE-nl-C1INH有关.
- 需要进一步的研究来阐明在基因不明的HAE-nl-C1INH病例中的机制.
相关概念视频
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
606
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
606
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
136
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
136
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
76
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
76
Antihypertensive Drugs: Angiotensin II Receptor Blockers
700
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
700
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419

